This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 06, 2012 4:30 pm ET
Gregory I. Frost - Co-Founder, Chief Executive Officer, President and Director
Kurt A. Gustafson - Chief Financial Officer, Principal Accounting Officer, Vice President and Secretary
John S. Sonnier - William Blair & Company L.L.C., Research Division
Jason N. Butler - JMP Securities LLC, Research Division
Christopher Holterhoff - Oppenheimer & Co. Inc., Research Division
Daniel Chung - Jefferies & Company, Inc., Research Division
Ying Huang - Barclays Capital, Research Division
Greetings, and welcome to the Halozyme Therapeutics Second Quarter 2012 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Anne Erickson, Executive Director of Investor Relations at Halozyme Therapeutics. Thank you, Ms. Erickson. You may begin your conference.
Good afternoon. Thank you for joining Halozyme's quarterly update conference call. With me on the call today are Gregory Frost, President and Chief Executive Officer; and Kurt Gustafson, Chief Financial Officer.
This afternoon, Halozyme released second quarter 2012 financial results. If you've not received this news release or if you'd like to be added to the company's distribution list, please e-mail me at email@example.com.
This call is also being webcast live over the Internet at www.halozyme.com, and a replay will be available on the company's website for the next 14 days.
Before we begin, let me remind you that during this conference call, we will be making forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides the Safe Harbor for forward-looking statements. All statements made during this conference call that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements could be affected by the risks and uncertainties of Halozyme's business, both known and unknown. Such risks inherent in the company's business are described in our filings with the Securities and Exchange Commission, as well as in our news releases. The company's actual results may differ materially from those expressed in or indicated by such forward-looking statements.